, Volume 42, Supplement 3, pp 22–24 | Cite as

Microbiological Conclusions

  • Ronald N. Jones


Cefaclor Cefixime Neisseria Gonorrhoeae Generation Cephalosporin Cefpodoxime 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Borin M. A review of the pharmacokinetics of cefpodoxime proxetil. Drugs 42 (Suppl. 3): 13–21, 1991PubMedCrossRefGoogle Scholar
  2. Fujii R. Clinical trials of cefpodoxime proxetil suspension in paediatrics. Drugs 42 (Suppl. 3): 57–60, 1991PubMedCrossRefGoogle Scholar
  3. Fujimoto K, Ishihara S, Yonagisawa H, Ide J, Nakayama E, et al. Studied on orally active cephalosporin esters. Journal of Antibiotics 40: 370–384, 1987PubMedCrossRefGoogle Scholar
  4. Jones R. Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cephems. Antimicrobial Newsletter 5: 1–7, 1988CrossRefGoogle Scholar
  5. Jones R, Barry A. In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition. Diagnostic Microbiology and Infectious Disease 8: 245–249, 1987PubMedCrossRefGoogle Scholar
  6. Jones R, Barry A. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrobial Agents and Chemotherapy 32: 443–449, 1988PubMedCrossRefGoogle Scholar
  7. Jones R, Barry A, Pfaller M, Allen S, Ayers L, et al. Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control. Diagnostic Microbiology and Infectious Disease 9: 59–63, 1988PubMedCrossRefGoogle Scholar
  8. Richmond M, Sykes R. The beta-lactamases of gram-negative bacteria and their possible physiological role. Advances in Microbial Physiology 9: 31, 1973PubMedCrossRefGoogle Scholar
  9. Tack KJ, Wilks NE, Semerdjian G, Frazier CH, Shirin K, et al. Cefpodoxime proxetil in the treatment of skin and soft tissue infections. Drugs 42 (Suppl. 3): 51–56, 1991PubMedCrossRefGoogle Scholar
  10. Utsui Y, Inoue M, Mitsuhashi S. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrobial Agents and Chemotherapy 31: 1085–1092, 1987PubMedCrossRefGoogle Scholar
  11. Wiedemann B, Luhmer E, Zühlsdorf MT. Microbiological evaluation of cefpodoxime proxetil. Drugs 42 (Suppl. 3): 6–12, 1991PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Ronald N. Jones
    • 1
  1. 1.Department of PathologyUniversity of Iowa Hospitals and ClinicsIowa CityUSA

Personalised recommendations